Identification | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Alseroxylon | ||||||||||||||||
Accession Number | DB00386 (APRD00786) | ||||||||||||||||
Type | small molecule | ||||||||||||||||
Description | A fat-soluble alkaloidal fraction extracted from the root of Rauwolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids; used as a sedative in psychoses, in mild hypertension, and as an adjunct to more potent hypotensive drugs. | ||||||||||||||||
Structure |
|
||||||||||||||||
Categories (*) | |||||||||||||||||
Molecular Weight | Not Available | ||||||||||||||||
Groups | approved | ||||||||||||||||
Monoisotopic Weight | Not Available | ||||||||||||||||
Pharmacology | |||||||||||||||||
Indication | For the treatment of hypertension and as an adjunct in the management of angina pectoris. | ||||||||||||||||
Mechanism of action | The antihypertensive actions of alseroxylon are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. Alseroxylon almost irreversibly blocks the accumulation of noradrenaline and dopamine into synaptic vesicles by inhibiting the Vesicular Monoamine Transporters (VMAT). This depletion ultimately affects the carotid pressoreceptors which leads to a decrease in vascular pressure. | ||||||||||||||||
Absorption | Not Available | ||||||||||||||||
Protein binding | Not Available | ||||||||||||||||
Biotransformation | Not Available | ||||||||||||||||
Route of elimination | Not Available | ||||||||||||||||
Toxicity | Not Available | ||||||||||||||||
Affected organisms |
|
||||||||||||||||
Interactions | |||||||||||||||||
Drug Interactions |
|
||||||||||||||||
Food Interactions | Not Available |
Synaptic vesicular amine transporter | |
---|---|
Name | Synaptic vesicular amine transporter |
Gene Name | SLC18A2 |
Pharmacological action | yes |
Actions | inhibitor |
References |
|
DTHybrid score | 0.5194 |